- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07939321
Cardiovascular Risk and Outcomes in Patients With Cancer: The TRACE-Cancer Study (TRACE-Cancer)
Cardiovascular Risk Stratification, Clinical Outcomes, and Prevention in Patients With Cancer: A Nationwide Multicenter Retrospective and Prospective Cohort Study
The goal of this observational study is to investigate cardiovascular risks and long-term outcomes in adults with cancer in China. The main questions it aims to answer are:What is the risk of major adverse cardiovascular events (MACE) in patients with different types of cancer and anticancer treatments?Can clinical characteristics, cardiovascular assessments, and biomarkers help predict cardiovascular events and identify high-risk patients?This nationwide, multicenter study includes both retrospective and prospective cohorts. Researchers will collect clinical information from medical records and follow participants over time to assess cardiovascular health and outcomes.Participants in the prospective cohort will undergo cardiovascular assessments and follow-up as part of their clinical care. No experimental treatments will be assigned.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
The TRACE-Cancer Study is a nationwide, multicenter, observational cohort study designed to evaluate cardiovascular risks and long-term outcomes in adults with cancer.The study includes a retrospective cohort of patients diagnosed between January 2018 and June 2026 and a prospective cohort enrolled from June 2026, with follow-up planned through December 2036.Clinical data will include cancer characteristics, anticancer treatments, cardiovascular risk factors, medical history, laboratory tests, cardiac imaging, and biomarkers. The primary outcome is major adverse cardiovascular events (MACE), including cardiovascular death, nonfatal myocardial infarction, hospitalization for heart failure, nonfatal stroke, and serious arrhythmias. Secondary outcomes include all-cause mortality, cancer-specific mortality, other cardiovascular complications, and changes in cardiac function.The study will also develop and validate cardiovascular risk prediction models to support early identification and prevention of cardiovascular complications in patients with cancer. All treatment decisions will follow routine clinical practice without study-assigned interventions.
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Guoliang Li
- Numéro de téléphone: 0086-2985323868
- E-mail: guoliangli@xjtu.edu.cn
Sauvegarde des contacts de l'étude
- Nom: Shi Tao
- Numéro de téléphone: 0086-2985323865
- E-mail: shitao068@xjtu.edu.cn
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
The study population consists of adults aged 18 years or older with pathologically or cytologically confirmed malignancies receiving cancer-related care at participating medical centers across China. The study includes two cohorts: a retrospective cohort of patients diagnosed and treated between January 2018 and June 2026, and a prospective cohort enrolling eligible patients from June 2026 onward. Participants will be recruited from general hospitals, cancer centers, and cardiovascular centers. All cancer types and stages are eligible, regardless of anticancer treatment or baseline cardiovascular status. Clinical information and long-term cardiovascular outcomes will be collected using standardized procedures. Biospecimen availability is not required for enrollment.
La description
Inclusion Criteria:
- Adults aged 18 years or older.
- Patients with a pathologically or cytologically confirmed diagnosis of malignancy.
- Patients receiving cancer-related diagnosis, treatment, clinical assessment, or follow-up at participating centers.
- For the retrospective cohort, availability of traceable clinical records, including medical history, pathology reports, treatment information, or follow-up data.
- For the prospective cohort, provision of informed consent by the participant or legally authorized representative, in accordance with applicable ethical requirements.
- Availability of baseline clinical information and the ability to obtain follow-up information through clinical records, outpatient visits, hospitalization records, telephone contact, or other approved sources.
Exclusion Criteria:
- Inability to confirm a diagnosis of malignancy.
- For the retrospective cohort, insufficient essential clinical information to establish baseline status or ascertain the primary outcome.
- For the prospective cohort, refusal to provide informed consent when required.
- Duplicate enrollment of the same participant at the same center; only the first eligible record will be retained.
- Other circumstances determined by the investigators to prevent appropriate participation or reliable follow-up.
Additional Consideration:
Patients will not be excluded based on cancer type, cancer stage, anticancer treatment modality, pre-existing cardiovascular conditions, comorbidities, or expected survival. The availability of biological specimens is not required for enrollment, and participants without available biospecimens will remain eligible for the clinical cohort.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: OTHER
Cohortes et interventions
Groupe / Cohorte |
|---|
|
Retrospective Cohort
Adults aged 18 years or older with pathologically or cytologically confirmed malignancies who received medical care at participating centers between January 2018 and June 2026. Clinical characteristics, anticancer treatments, cardiovascular risk factors, and long-term outcomes will be collected retrospectively from existing medical records and available follow-up data. |
|
Prospective Cohort
Adults aged 18 years or older with pathologically or cytologically confirmed malignancies who are prospectively enrolled at participating centers beginning in June 2026. Clinical characteristics, anticancer treatments, cardiovascular assessments, and outcomes will be collected at baseline and during longitudinal follow-up through December 2036. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Time to First Major Adverse Cardiovascular Event (MACE)
Délai: From baseline to the first qualifying event or the end of follow-up, up to 10 years.
|
Time from baseline to the first occurrence of a major adverse cardiovascular event (MACE), defined as a composite of cardiovascular death, nonfatal myocardial infarction, hospitalization for heart failure, nonfatal ischemic or hemorrhagic stroke, or serious arrhythmia. Serious arrhythmias include sustained ventricular tachycardia, ventricular fibrillation, resuscitated cardiac arrest, arrhythmias requiring electrical cardioversion or defibrillation, severe bradyarrhythmias requiring permanent pacemaker implantation, and clinically significant new-onset atrial fibrillation or atrial flutter associated with hemodynamic compromise. The first qualifying event will be identified through medical records and follow-up information and adjudicated according to standardized diagnostic criteria. |
From baseline to the first qualifying event or the end of follow-up, up to 10 years.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Time to All-Cause Mortality
Délai: From baseline to death or the end of follow-up, up to 10 years.
|
Time from baseline to death from any cause. Death events and dates will be identified using hospital medical records, available death registration information, and follow-up records. The cumulative incidence and time to all-cause mortality will be assessed during follow-up. |
From baseline to death or the end of follow-up, up to 10 years.
|
|
Time to Cancer-Specific Mortality
Délai: From baseline to cancer-related death or the end of follow-up, up to 10 years.
|
Time from baseline to death attributed to the underlying malignancy or cancer-related complications. Cancer-specific mortality will be determined based on available medical records, documented causes of death, and follow-up information. Deaths from other causes will be treated as competing events in the analysis of cancer-specific mortality. |
From baseline to cancer-related death or the end of follow-up, up to 10 years.
|
|
Time to Cardiovascular Death
Délai: From baseline to cardiovascular death or the end of follow-up, up to 10 years.
|
Time from baseline to death attributed to cardiovascular causes, including fatal myocardial infarction, heart failure, stroke, sudden cardiac death, or other cardiovascular conditions. Cardiovascular death will be determined using available medical records, documented causes of death, and standardized adjudication criteria. Noncardiovascular deaths will be treated as competing events. |
From baseline to cardiovascular death or the end of follow-up, up to 10 years.
|
|
Time to First Nonfatal Myocardial Infarction
Délai: From baseline to the first nonfatal myocardial infarction or the end of follow-up, up to 10 years.
|
Time from baseline to the first nonfatal myocardial infarction during follow-up. Myocardial infarction will be identified from clinical records and hospitalization data and confirmed according to standardized diagnostic criteria, including clinical presentation, cardiac troponin measurements, electrocardiographic findings, and available cardiac imaging or coronary angiographic evidence. |
From baseline to the first nonfatal myocardial infarction or the end of follow-up, up to 10 years.
|
|
Time to First Hospitalization for Heart Failure
Délai: From baseline to the first hospitalization for heart failure or the end of follow-up, up to 10 years.
|
Time from baseline to the first hospitalization for newly diagnosed or worsening heart failure requiring inpatient treatment. Heart failure events will be identified through hospitalization records and confirmed using clinical symptoms, signs, cardiac imaging findings, laboratory results, and standardized diagnostic criteria. |
From baseline to the first hospitalization for heart failure or the end of follow-up, up to 10 years.
|
|
Time to First Nonfatal Stroke
Délai: From baseline to the first nonfatal stroke or the end of follow-up, up to 10 years.
|
Time from baseline to the first nonfatal stroke, including ischemic and hemorrhagic stroke. Stroke events will be identified through clinical records, hospitalization data, and available neuroimaging findings and confirmed according to standardized diagnostic criteria. |
From baseline to the first nonfatal stroke or the end of follow-up, up to 10 years.
|
|
Time to First Serious Arrhythmia
Délai: From baseline to the first qualifying serious arrhythmia or the end of follow-up, up to 10 years.
|
Time from baseline to the first occurrence of a serious arrhythmia, including sustained ventricular tachycardia, ventricular fibrillation, resuscitated cardiac arrest, arrhythmias requiring electrical cardioversion or defibrillation, severe bradyarrhythmias requiring permanent pacemaker implantation, and clinically significant new-onset atrial fibrillation or atrial flutter associated with hemodynamic compromise. Events will be identified through electrocardiograms, ambulatory electrocardiographic monitoring, implanted cardiac device records, hospitalization records, and clinical documentation. |
From baseline to the first qualifying serious arrhythmia or the end of follow-up, up to 10 years.
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in Plasma N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) Concentration
Délai: Baseline and available follow-up assessments through 10 years.
|
Change in plasma NT-proBNP concentration from baseline to follow-up, measured using validated clinical laboratory immunoassays and reported in pg/mL. Absolute changes in NT-proBNP concentration will be calculated among participants with available baseline and follow-up measurements. Exploratory analyses will examine the relationship between NT-proBNP levels and cardiovascular outcomes, particularly heart failure events, in participants with available clinical data and biospecimens. |
Baseline and available follow-up assessments through 10 years.
|
|
Change in Circulating Cardiac Troponin Concentration
Délai: Baseline and available follow-up assessments through 10 years.
|
Change in circulating cardiac troponin concentration from baseline to follow-up, measured using validated clinical laboratory cardiac troponin assays and reported in assay-specific concentration units. Absolute changes will be evaluated among participants with available baseline and follow-up measurements. Exploratory analyses will investigate the relationship between circulating cardiac troponin concentrations and cardiovascular outcomes, particularly myocardial injury and major adverse cardiovascular events. |
Baseline and available follow-up assessments through 10 years.
|
Collaborateurs et enquêteurs
Les enquêteurs
- Chercheur principal: Guoliang Li, First Affiliated Hospital Xi'an Jiaotong University
- Chercheur principal: Tao Shi, First Affiliated Hospital Xi'an Jiaotong University
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- XJTU1AF2026LSYY-0455
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .